/BMEA
BMEA Stock - Biomea Fusion, Inc.
Healthcare|BiotechnologyNASDAQ
$1.40+3.70%
+$0.05 (+3.70%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.31
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+614.3%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BMEA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.39 – $1.41
TARGET (TP)$10.00
STOP LOSS$1.29
RISK/REWARD1:78.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.16
52W High$4.59
52W Low$0.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-132,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-144,070,000 | $-126,135,000 | $-83,634,000 | $-41,667,000 | $-5,327,000 |
| Net Income | $-138,426,000 | $-117,255,000 | $-81,828,000 | $-41,567,000 | $-5,324,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.83 | $-3.44 | $-2.80 | $-1.74 | $-0.50 |
Company Overview
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
69%
Hold / Neutral
4
31%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
9 Bullish4 Neutral/Bearish
Price Targets
$29
Average Target
↑ 1945.9% Upside
Now
$5
Low
$29
Average
$55
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 28th 2025 | Jefferies | Initiation | Buy | $5 |
| June 3rd 2025 | Piper Sandler | Resumed | Overweight | $7 |
| September 27th 2024 | Rodman & Renshaw | Upgrade | Buy | $18 |
| September 27th 2024 | Truist | Upgrade | Buy | $54 |
| August 29th 2024 | CapitalOne | Initiation | Overweight | $25 |
| June 11th 2024 | Truist | Downgrade | Hold | - |
| June 7th 2024 | Barclays | Downgrade | Equal Weight | $5← $30 |
| April 2nd 2024 | JP Morgan | Downgrade | Neutral | $14← $51 |
| February 6th 2024 | Truist | Initiation | Buy | $55 |
| July 27th 2023 | Scotiabank | Initiation | Sector Outperform | $41 |
| June 26th 2023 | Jefferies | Downgrade | Hold | - |
| May 12th 2023 | Barclays | Initiation | Overweight | $50 |
| March 29th 2023 | Oppenheimer | Reiterated | Outperform | $47← $25 |
| March 28th 2023 | H.C. Wainwright | Reiterated | Buy | $44← $37 |
| February 24th 2023 | Citigroup | Initiation | Buy | $20 |
Earnings History & Surprises
BMEABeat Rate
37%
Last 19 quarters
Avg Surprise
-17.2%
EPS vs Estimate
Beats / Misses
7/11
1 met exactly
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q2 24
-15.3%
$-0.98vs$-0.85
Q2 24
-6.9%
$-1.09vs$-1.02
Q3 24
0.0%
$-1.03vs$-1.03
Q4 24
+13.3%
$-0.91vs$-1.05
Q1 25
+19.0%
$-0.81vs$-1.00
Q2 25
+4.8%
$-0.80vs$-0.84
Q3 25
+13.6%
$-0.51vs$-0.59
Q4 25
-3.8%
$-0.27vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.25 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.26 | $-0.27 | -3.8% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.59 | $-0.51 | +13.6% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.84 | $-0.80 | +4.8% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-1.00 | $-0.81 | +19.0% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $-1.05 | $-0.91 | +13.3% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-1.03 | $-1.03 | 0.0% | = MET |
Q2 2024 | May 2, 2024 | $-1.02 | $-1.09 | -6.9% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.85 | $-0.98 | -15.3% | ✗ MISS |
Q4 2023 | Oct 30, 2023 | $-0.83 | $-0.80 | +3.6% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $-0.86 | $-0.70 | +18.6% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.80 | $-0.98 | -22.5% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.81 | $-0.86 | -6.2% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.65 | $-0.78 | -20.0% | ✗ MISS |
Q3 2022 | Aug 1, 2022 | $-0.60 | $-0.59 | +1.7% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.53 | $-0.56 | -5.7% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.45 | $-0.51 | -13.3% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.40 | $-0.43 | -7.5% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.22 | $-0.33 | -50.0% | ✗ MISS |
Q2 2021 | May 27, 2021 | $-0.14 | $-0.49 | -250.0% | ✗ MISS |
Latest News
Reported Earlier, Biomea Fusion Spotlights WCIRDC 2025 Discussion Of Menin Inhibition And Icovamenib, Including Combination Data With GLP-1 Based Therapies
➖ NeutralBenzinga•Dec 10, 2025, 08:39 AM
Biomea Fusion shares are trading higher after the company announced that it presented COVALENT-111 study results at the 23rd WCIRDC.
📈 PositiveBenzinga•Dec 5, 2025, 02:13 PM
Biomea Fusion Reports Durable Glycemic And C-Peptide Improvements 9 Months After Last Dose In COVALENT-111 With Icovamenib
📈 PositiveBenzinga•Dec 5, 2025, 12:08 PM
Biomea Fusion Has Been Selected For An Oral Presentation Of Its Long-Term Icovamenib Follow Up Data At The 23rd World Congress On Insulin Resistance, Diabetes & Cardiovascular Disease Taking Place In Los Angeles, California On December 3-6, 2025
📈 PositiveBenzinga•Dec 1, 2025, 09:13 PM
Citigroup Maintains Buy on Biomea Fusion, Lowers Price Target to $6
➖ NeutralBenzinga•Nov 10, 2025, 09:45 PM•Also:
D. Boral Capital Maintains Buy on Biomea Fusion, Lowers Price Target to $12
📈 PositiveBenzinga•Nov 5, 2025, 01:39 PM
Biomea Fusion Presents Preclinical Data For BMF-650 Oral Small Molecule GLP-1 At ObesityWeek In Atlanta
➖ NeutralBenzinga•Nov 5, 2025, 12:17 PM
Biomea Fusion Q3 EPS $(0.27) Misses $(0.26) Estimate
📉 NegativeBenzinga•Nov 4, 2025, 09:46 PM
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 12:40 PM
Biomea Fusion Doses First Patient In Phase I Study Of BMF-650
📈 PositiveBenzinga•Oct 27, 2025, 12:12 PM
Biomea Fusion shares are trading lower after the company announced pricing of its underwritten public offering including 11,195,121 shares of common stock and 1 million pre-funded warrants at an excise price of $2.50.
📉 NegativeBenzinga•Oct 7, 2025, 04:01 PM
Biomea Fusion Announces Pricing Of Its Underwritten Public Offering Including 11,195,121 Shares Of Common Stock And 1M Pre-Funded Warrants. Each Warrant Has Exercise Price Of $2.50 And Offering Price Per Common Share And Warrant Is $2.05
➖ NeutralBenzinga•Oct 7, 2025, 12:05 PM
Biomea Fusion Announces Proposed Public Offering Of Securities; No Size Or Amount Disclosed
➖ NeutralBenzinga•Oct 6, 2025, 08:18 PM
Biomea Fusion shares are trading higher after the company announced 52-week results from its Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes.
📈 PositiveBenzinga•Oct 6, 2025, 08:04 PM
Biomea Fusion Announces 52-Week Phase II Data For Icovamenib In Type 2 Diabetes; Study Shows Sustained HbA1c Reduction And Favorable Safety Profile
📈 PositiveBenzinga•Oct 6, 2025, 08:04 PM
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
📈 PositiveBenzinga•Oct 3, 2025, 12:32 PM
Biomea Fusion Presents Data Showing Icovamenib + Semaglutide Boosts T2D Outcomes; FDA Clears IND For BMF-650, Phase I Obesity Trial In 2025
📈 PositiveBenzinga•Sep 16, 2025, 11:17 AM
Jefferies Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $5
📈 PositiveBenzinga•Aug 28, 2025, 12:31 PM
Biggest stock movers Wednesday: UBS, BTDR, and more
➖ NeutralSeeking Alpha•Jun 18, 2025, 09:00 AM•Also: , ,
Biomea Fusion sinks 25%, prices $40M stock offering
📉 NegativeSeeking Alpha•Jun 18, 2025, 06:39 AM
Frequently Asked Questions about BMEA
What is BMEA's current stock price?
Biomea Fusion, Inc. (BMEA) is currently trading at $1.40 per share. The stock has moved +3.70% today.
What is the analyst price target for BMEA?
The average analyst price target for BMEA is $10.00, based on 1 analyst.
What sector is Biomea Fusion, Inc. in?
Biomea Fusion, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BMEA's market cap?
Biomea Fusion, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does BMEA pay dividends?
No, Biomea Fusion, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
Explore stocks similar to BMEA for comparison